# HIV

## Length of Authorizations

365 Days

## Grandfathering

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Abacavir/Dolutegravir/Lamivudine

Abacavir/Dolutegravir/Lamivudine (Triumeq PD) Criteria

-   Must provide documentation of patient’s weight (only authorized for those 10 – 25 kg)

### Fostemsavir

Fostemsavir (Rukobia ER) Criteria

-   Must provide documentation of a multidrug-resistant HIV-1 infection

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug. If applicable, the request must address the inability to use the individual components.
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Darunavir/Cobicistat/Emtricitabine/Tenofovir

Additional Darunavir/Cobicistat/Emtricitabine/Tenofovir (Symtuza) Criteria

-   Must provide documentation for patient’s inability to use the individual drugs (Prezcobix and Descovy)

### Subsequent Authorization

-   Must provide information of patient’s clinical response to treatment and ongoing safety monitoring

**AR** – Isentress chewable tablet: a PA is required for patients 12 years and older

## Formulary

Infectious Disease Agents: Antivirals – HIV

### Preferred

| Preferred                                   |      |
| :------------------------------------------ | ---: |
| Abacavir Sulfate                            |      |
| Abacavir/Lamivudine                         |      |
| Atazanavir Sulfate                          |      |
| Biktarvy                                    |      |
| Cimduo                                      |      |
| Complera                                    |      |
| Delstrigo                                   |      |
| Descovy                                     |      |
| Dovato                                      |      |
| Efavirenz                                   |      |
| Efavirenz/Emtricitabine/Tenofovir           |      |
| Emtricitabine/Tenofovir Disoproxil Fumarate |      |
| Emtriva BvG                                 |      |
| Evotaz                                      |      |
| Genvoya                                     |      |
| Isentress Chew Tab AR                       |      |
| Isentress                                   |      |
| Juluca                                      |      |
| Kaletra Tab BvG                             |      |
| Norvir Tab BvG                              |      |
| Odefsey                                     |      |
| Pifeltro                                    |      |
| Prezcobix                                   |      |
| Prezista                                    |      |
| Rukobia ER PA                               |      |
| Symfi BvG                                   |      |
| Symfi Lo BvG                                |      |
| Temixys                                     |      |
| Tenofovir Disoproxil 300mg                  |      |
| Tivicay                                     |      |
| Tivicay PD                                  |      |
| Triumeq                                     |      |
| Triumeq PD PA                               |      |
| Viread                                      |      |
| Viread Oral Powder                          |      |
| Zidovudine                                  |      |

### Non-Preferred

| Non-Preferred                                      |      |
| :------------------------------------------------- | ---: |
| Abacavir Susp                                      |      |
| Abacavir/Lamivudine/Zidovudine                     |      |
| Aptivus                                            |      |
| Didanosine                                         |      |
| Edurant                                            |      |
| Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate |      |
| Emtricitabine                                      |      |
| Fosamprenavir                                      |      |
| Fuzeon                                             |      |
| Intelence BvG                                      |      |
| Lamivudine                                         |      |
| Lamivudine/Zidovudine                              |      |
| Lopinavir/Ritonavir                                |      |
| Nevirapine                                         |      |
| Norvir Powder, Sol                                 |      |
| Ritonavir Tab                                      |      |
| Selzentry BvG                                      |      |
| Stavudine                                          |      |
| Stribild                                           |      |
| Symtuza                                            |      |
| Tybost                                             |      |
| Viracept                                           |      |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=81)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=27)
